- Home
- EHAB vs FULC Comparison
EHAB vs FULC Comparison
Compare EHAB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHAB | FULC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.8M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EHAB | FULC |
|---|---|---|
| Price | $9.58 | $12.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $8.50 | ★ $16.38 |
| AVG Volume (30 Days) | 544.8K | ★ 2.6M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,047,800,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.02 | ★ 2752.05 |
| 52 Week Low | $6.47 | $2.32 |
| 52 Week High | $10.91 | $15.74 |
Technical Indicators
Market Signals| Indicator | EHAB | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 56.79 |
| Support Level | $9.50 | $11.98 |
| Resistance Level | $9.75 | $13.26 |
| Average True Range (ATR) | 0.26 | 1.22 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 55.47 | 51.06 |
Price Performance
Historical ComparisonAbout EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.